<DOC>
	<DOCNO>NCT01598103</DOCNO>
	<brief_summary>This study ass safety , tolerability efficacy SAF312 patient overactive bladder disease due spinal cord lesion . The overactive bladder patient qualify study insufficiently manage antimuscarinic therapy , patient poorly tolerate treatment antimuscarinic drug . The efficacy SAF312 primarily determine via urodynamic measurement .</brief_summary>
	<brief_title>Safety Efficacy SAF312 Patients With Neurogenic Detrusor Overactivity Due Spinal Cord Lesions</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<criteria>Patients neurogenic detrusor overactivity due spinal cord lesion Patients inadequately manage antimuscarinic medication present cystometric bladder capacity max . 400 mL Chronic inflammation interstitial cystitis , bladder stone , hematuria unknown origin , previous pelvic radiation therapy previous current malignant disease pelvic organ Pelvic genitourinary tract anomaly include surgery bladder disease detrusor overactivity impact bladder function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Neurogenic detrusor overactivity</keyword>
	<keyword>spinal cord lesion</keyword>
	<keyword>spinal cord injury</keyword>
</DOC>